Cenomed BioSciences Joins Forces with U.S. Army Medical Research Institute of Chemical Defense to Evaluate Therapeutics for Use in Chemical Defense

IRVINE, Calif.--(BUSINESS WIRE)--Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, Inc. (NASDAQ:ABBI), today announced that it has signed a three-year cooperative research and development agreement (CRADA) with the United States Army Medical Research Institute of Chemical Defense (USAMRICD) to evaluate Cenomed’s lead investigational compound CM-2,501 and other associated compounds, for the prevention of toxicities following exposure to chemical warfare agents. Cenomed’s compounds are being developed as a pre- and post-exposure therapy for military and civilian victims of a chemical nerve agent attack. Financial terms of the agreement were not disclosed.